TY - JOUR
T1 - Effects of intense pulsed light on tear film tgf-β and microbiome in ocular rosacea with dry eye
AU - Sagaser, Samantha
AU - Butterfield, Richard
AU - Kosiorek, Heidi
AU - Kusne, Yael
AU - Maldonado, Juan
AU - Fautsch, Michael P.
AU - Patel, Dharmendra
AU - Shen, Joanne F.
N1 - Funding Information:
This study was supported by Mayo Clinic Internal Funding and received research funding from Ocugen Pharmaceuticals for Joanne F Shen.
Publisher Copyright:
© 2021 Sagaser et al.
PY - 2021
Y1 - 2021
N2 - Purpose: To assess tear film transforming growth factor-beta (TGF-β) and ocular micro-biome changes after intense pulsed light with meibomian gland expression (IPL-MGX) vs only MGX in treating ocular rosacea with dry eye symptoms. Methods: Twenty patients were randomly assigned to IPL-MGX or MGX. Patients were examined, treated, and administered the ocular surface disease index (OSDI) survey every 4–6 weeks for four total treatments. Tear film and conjunctival samples were collected at first and last visits, and analyzed for TGF-β concentration and 16s rRNA amplicon sequencing of ocular microbiome. Wilcoxon Rank Sum and Sign-Rank were used to examine changes from baseline. Results: OSDI revealed significantly greater improvement in symptoms after IPL-MGX (p=0.030) compared to MGX. There was no significant difference in mean TGF-β1, 2, or 3 concentration after IPL-MGX (p=0.385, 0.709, 0.948, respectively). Quantities of Clostridium, Klebsiella, Brevibacterium, Lactobacillus, Neisseria, Streptococcus, Corynebacterium, Butyricicoccus, and Actinomyces were significantly reduced from baseline in both groups but without a significant difference between the two treatment groups. Conclusion: IPL-MGX improved dry eye symptoms more than MGX alone. IPL treatment offered no additional benefit to MGX in decreasing virulent bacteria present on the ocular surface and did not influence TGF-β levels in tears. Prospective studies on IPL-MGX with larger sample sizes are needed to further investigate cytokines and IPL in patients suffering from ocular rosacea with dry eye symptoms.
AB - Purpose: To assess tear film transforming growth factor-beta (TGF-β) and ocular micro-biome changes after intense pulsed light with meibomian gland expression (IPL-MGX) vs only MGX in treating ocular rosacea with dry eye symptoms. Methods: Twenty patients were randomly assigned to IPL-MGX or MGX. Patients were examined, treated, and administered the ocular surface disease index (OSDI) survey every 4–6 weeks for four total treatments. Tear film and conjunctival samples were collected at first and last visits, and analyzed for TGF-β concentration and 16s rRNA amplicon sequencing of ocular microbiome. Wilcoxon Rank Sum and Sign-Rank were used to examine changes from baseline. Results: OSDI revealed significantly greater improvement in symptoms after IPL-MGX (p=0.030) compared to MGX. There was no significant difference in mean TGF-β1, 2, or 3 concentration after IPL-MGX (p=0.385, 0.709, 0.948, respectively). Quantities of Clostridium, Klebsiella, Brevibacterium, Lactobacillus, Neisseria, Streptococcus, Corynebacterium, Butyricicoccus, and Actinomyces were significantly reduced from baseline in both groups but without a significant difference between the two treatment groups. Conclusion: IPL-MGX improved dry eye symptoms more than MGX alone. IPL treatment offered no additional benefit to MGX in decreasing virulent bacteria present on the ocular surface and did not influence TGF-β levels in tears. Prospective studies on IPL-MGX with larger sample sizes are needed to further investigate cytokines and IPL in patients suffering from ocular rosacea with dry eye symptoms.
KW - Dry eye disease
KW - IPL
KW - Intense pulsed light
KW - Meibomian gland disorder
KW - Meibomian gland expression
KW - OSDI; ocular surface disease index
KW - Ocular microbiome
KW - Ocular rosacea
KW - TGF-β
KW - Tear cytokines
KW - Transforming growth factor-beta
UR - http://www.scopus.com/inward/record.url?scp=85100331926&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100331926&partnerID=8YFLogxK
U2 - 10.2147/OPTH.S280707
DO - 10.2147/OPTH.S280707
M3 - Article
AN - SCOPUS:85100331926
SN - 1177-5467
VL - 15
SP - 323
EP - 330
JO - Clinical Ophthalmology
JF - Clinical Ophthalmology
ER -